Logo image of ACLX

ARCELLX INC (ACLX) Stock Overview

NASDAQ:ACLX - US03940C1009 - Common Stock

69.9 USD
0 (0%)
Last: 8/27/2025, 4:30:00 PM
69.9 USD
0 (0%)
After Hours: 8/27/2025, 4:30:00 PM

ACLX Key Statistics, Chart & Performance

Key Statistics
52 Week High107.37
52 Week Low47.86
Market Cap3.88B
Shares55.46M
Float44.99M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-3.42
PEN/A
Fwd PEN/A
Earnings (Next)11-18 2025-11-18/amc
IPO02-04 2022-02-04
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


ACLX short term performance overview.The bars show the price performance of ACLX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 10

ACLX long term performance overview.The bars show the price performance of ACLX in the last 1, 2 and 3 years. 1 year 2 years 3 years 50 100 150 200 250

The current stock price of ACLX is 69.9 USD. In the past month the price decreased by -2.29%. In the past year, price increased by 1.69%.

ARCELLX INC / ACLX Daily stock chart

ACLX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.65 367.55B
AMGN AMGEN INC 13.2 155.03B
GILD GILEAD SCIENCES INC 14.72 141.35B
VRTX VERTEX PHARMACEUTICALS INC 22.97 99.76B
REGN REGENERON PHARMACEUTICALS 12.86 62.21B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 59.53B
ARGX ARGENX SE - ADR 76.37 43.33B
ONC BEONE MEDICINES LTD-ADR 6.06 35.68B
INSM INSMED INC N/A 28.44B
BNTX BIONTECH SE-ADR N/A 24.76B
NTRA NATERA INC N/A 22.38B
BIIB BIOGEN INC 8.52 19.99B

About ACLX

Company Profile

ACLX logo image Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company is headquartered in Redwood City, California and currently employs 163 full-time employees. The company went IPO on 2022-02-04. Its lead program is a BCMA-targeting ddCAR product candidate called anitocabtagene autoleucel, which is being evaluated in its pivotal Phase II iMMagine-1 and the Phase III iMMagine-3 trials in patients with relapsed or refractory multiple myeloma (rrMM). Anitocabtagene is the first BCMA-directed CAR T-cell therapy to be investigated in multiple myeloma that utilizes its novel and compact binder known as the D-Domain. The small, stable D-Domain binder enables high CAR expression without tonic signaling and is designed to quickly release from the BCMA target. The company is also developing two clinical-stage ARC-SparX programs in Phase I trials: ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).

Company Info

ARCELLX INC

800 Bridge Parkway

Redwood City CALIFORNIA US

Employees: 163

ACLX Company Website

ACLX Investor Relations

Phone: 12403270603

ARCELLX INC / ACLX FAQ

What is the stock price of ARCELLX INC today?

The current stock price of ACLX is 69.9 USD.


What is the ticker symbol for ARCELLX INC stock?

The exchange symbol of ARCELLX INC is ACLX and it is listed on the Nasdaq exchange.


On which exchange is ACLX stock listed?

ACLX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ARCELLX INC stock?

25 analysts have analysed ACLX and the average price target is 115.33 USD. This implies a price increase of 64.99% is expected in the next year compared to the current price of 69.9. Check the ARCELLX INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ARCELLX INC worth?

ARCELLX INC (ACLX) has a market capitalization of 3.88B USD. This makes ACLX a Mid Cap stock.


How many employees does ARCELLX INC have?

ARCELLX INC (ACLX) currently has 163 employees.


What are the support and resistance levels for ARCELLX INC (ACLX) stock?

ARCELLX INC (ACLX) has a support level at 69.89 and a resistance level at 72.74. Check the full technical report for a detailed analysis of ACLX support and resistance levels.


Is ARCELLX INC (ACLX) expected to grow?

The Revenue of ARCELLX INC (ACLX) is expected to decline by -59.75% in the next year. Check the estimates tab for more information on the ACLX EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ARCELLX INC (ACLX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ARCELLX INC (ACLX) stock pay dividends?

ACLX does not pay a dividend.


When does ARCELLX INC (ACLX) report earnings?

ARCELLX INC (ACLX) will report earnings on 2025-11-18, after the market close.


What is the Price/Earnings (PE) ratio of ARCELLX INC (ACLX)?

ARCELLX INC (ACLX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.42).


What is the Short Interest ratio of ARCELLX INC (ACLX) stock?

The outstanding short interest for ARCELLX INC (ACLX) is 14.55% of its float. Check the ownership tab for more information on the ACLX short interest.


ACLX Technical Analysis

ChartMill assigns a technical rating of 5 / 10 to ACLX. When comparing the yearly performance of all stocks, ACLX turns out to be only a medium performer in the overall market: it outperformed 56.45% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ACLX Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ACLX. ACLX has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ACLX Financial Highlights

Over the last trailing twelve months ACLX reported a non-GAAP Earnings per Share(EPS) of -3.42. The EPS decreased by -228.85% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -30.37%
ROE -47.93%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-84.31%
Sales Q2Q%-72.41%
EPS 1Y (TTM)-228.85%
Revenue 1Y (TTM)-60.64%

ACLX Forecast & Estimates

25 analysts have analysed ACLX and the average price target is 115.33 USD. This implies a price increase of 64.99% is expected in the next year compared to the current price of 69.9.

For the next year, analysts expect an EPS growth of -106.46% and a revenue growth -59.75% for ACLX


Analysts
Analysts85.6
Price Target115.33 (64.99%)
EPS Next Y-106.46%
Revenue Next Year-59.75%

ACLX Ownership

Ownership
Inst Owners96.7%
Ins Owners2.31%
Short Float %14.55%
Short Ratio12.29